Kim Hyo Jung, Kim Jae Seon, Suh Sang Jun, Lee Beom Jae, Park Jong-Jae, Lee Hong Sik, Kim Chang Duck, Bak Young-Tae
Division of Gastroenterology, Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, 148 Gurogong-gil, Guro-gu, Seoul, 152-703, Korea,
World J Surg. 2015 Jun;39(6):1537-42. doi: 10.1007/s00268-015-2965-0.
Hepatolithiasis is a well-known risk factor of cholangiocarcinoma. Despite advances in diagnostic modalities, diagnosing cholangiocarcinoma in patients with hepatolithiasis still challenging and there are not enough reports on the incidence of cholangiocarcinoma in patient with hepatolithiasis after treatment. We aimed to evaluate the incidence and clinical characteristics of cholangiocarcinoma in patients with hepatolithiasis who underwent liver resection or non-resection.
Among a total of 257 patients who received treatment for hepatolithiasis, 236 patients were eligible for analysis. Exclusion criteria were follow-up period less than 9 months, preoperative diagnosis of cholangiocarcinoma, occurrence of cholangiocarcinoma within 1 year after treatment. Completeness of stone clearance was defined when there was no intrahepatic duct stone during whole follow-up period. A retrospective study was done to analyze the patients' characteristics, the results and complications of the procedure, and the long-term outcomes for these patients. Kaplan-Meier method and cox proportional regression were used for statistical analysis.
95 patients underwent hepatic resection (resection group) and 144 patients did not (non-resection group). Complete stone clearance was 71% (67/95) in resection group and 41% (58/141) in non-resection group (p < 0.001). The incidence of cholangiocarcinoma was 6.8% (16/236) during follow-up period (mean 41 ± 41 months). Cholangiocarcinoma occurred 6.3% (6/95) and 7.1% (10/141) in resection and non-resection group, respectively. There was no significant difference in survival between two groups (p = 0.254). In analysis of according to completeness of stone clearance regardless of treatment modality, cholangiocarcinoma incidence was higher in patients with residual stone (10.4%) than complete stone removal (3.3%) (p = 0.263). On multivariate analysis, none of the factors (age, gender, CA19-9, stone location, bile duct stenosis, liver atrophy, stone recurrence, residual stone, and hepatic resection) showed relationship with the incidence of cholangiocarcinoma.
Hepatic resection for hepatolithiasis is considered to have a limited value in preventing cholangiocarcinoma and the patients should be carefully followed even after hepatic resection. A combination of different treatment modalities is necessary to decrease the residual stone and improve the outcome of the patients with hepatolithiasis.
肝内胆管结石是胆管癌的一个众所周知的危险因素。尽管诊断方式有所进步,但在肝内胆管结石患者中诊断胆管癌仍然具有挑战性,并且关于肝内胆管结石患者治疗后胆管癌发病率的报道不足。我们旨在评估接受肝切除或非切除治疗的肝内胆管结石患者胆管癌的发病率和临床特征。
在总共257例接受肝内胆管结石治疗的患者中,236例符合分析条件。排除标准为随访期少于9个月、术前诊断为胆管癌、治疗后1年内发生胆管癌。当整个随访期内无肝内胆管结石时,定义结石清除完全。进行回顾性研究以分析患者的特征、手术结果和并发症以及这些患者的长期预后。采用Kaplan-Meier法和Cox比例回归进行统计分析。
95例患者接受了肝切除(切除组),144例患者未接受肝切除(非切除组)。切除组的结石完全清除率为71%(67/95),非切除组为41%(58/141)(p<0.001)。随访期间胆管癌的发病率为6.8%(16/236)(平均41±41个月)。切除组和非切除组胆管癌的发生率分别为6.3%(6/95)和7.1%(10/141)。两组之间的生存率无显著差异(p=0.254)。在根据结石清除情况进行分析时,无论治疗方式如何,残留结石患者的胆管癌发病率(10.4%)高于结石完全清除患者(3.3%)(p=0.263)。多因素分析显示,没有任何因素(年龄、性别、CA19-9、结石位置、胆管狭窄、肝萎缩、结石复发、残留结石和肝切除)与胆管癌的发病率相关。
肝内胆管结石的肝切除在预防胆管癌方面的价值有限,即使在肝切除后也应对患者进行仔细随访。需要联合不同的治疗方式以减少残留结石并改善肝内胆管结石患者的预后。